S. Vincent Rajkumar, MD

S. Vincent Rajkumar, MD

Mayo Clinic

Latest Content

Group photo of four medical professionals, including Dr. Shaji Kumar, Dr. Vincent Rajkumar, Dr. Rahul Gosain, and Dr. Rohit Gosain, discussing findings from ENDURANCE trial for multiple myeloma.

Hematology

08/05/2026

Findings From ENDURANCE Trial Offer New Standard of Care for Multiple Myeloma

Panel discussion on partnerships and outpatient strategies for bispecifics in multiple myeloma with Dr. S. Vincent Rajkumar, Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Beth Faiman, and Dr. Rafael Fonseca.

Second Line and Beyond

07/10/2026

Ep 4. Community Perspective: Partnerships and Outpatient Strategies for Bispecifics in Multiple Myeloma 

OncUpdates episode 3 features Dr. S. Vincent Rajkumar discussing managing side effects of BCMA bispecifics and Talquetamab in myeloma treatment.

Second Line and Beyond

07/09/2026

Ep 3. Managing Side Effects BCMA Bispecifics and Talquetamab in Myeloma

OncUpdates Episode 2 features Dr. S. Vincent Rajkumar discussing bispecifics: MajesTEC-3, MajesTEC-9, and MonumenTAL-3 with expert panel.

Second Line and Beyond

07/08/2026

Ep 2. The Advent of Bispecifics: MajesTEC-3, MajesTEC-9, and MonumenTAL-3

Dr. S. Vincent Rajkumar and colleagues discuss a new algorithm for second-line treatment of multiple myeloma in a medical webinar.

Second Line and Beyond

07/07/2026

Ep 1. The New Algorithm for Second-Line Treatment of Multiple Myeloma

Group of medical professionals discussing evolving treatment landscape in second-line and beyond multiple myeloma, with cityscape background.

Second Line and Beyond

06/26/2026

Evolving Treatment Landscape in Second-Line and Beyond Multiple Myeloma

Quality image showing Dr. Vincent Rajkumar, Dr. Rahul Gosain, and Dr. Rohit Gosain discussing Aquila Trial Insights on Daratumumab for high-risk smoldering myeloma treatment, featured on OncUpdates.

Hematology

02/21/2026

AQUILA Trial Insights: Daratumumab for the Treatment of High-Risk Smoldering Myeloma

1. Researchers and clinicians discuss strategies for managing lenalidomide, CD38, and multi-refractory disease in relapsed multiple myeloma treatment at OncUpdates conference.

Multiple Myeloma

01/04/2026

How to Select Treatment in Relapsed Multiple Myeloma